Literature DB >> 3936718

Synergy of B cell growth factor and interleukin 2 in the proliferation of activated human B cells.

S Romagnani, G M Giudizi, E Maggi, F Almerigogna, R Biagiotti, G Del Prete, M Mazzetti, A Alessi, D Vercelli, M Ricci.   

Abstract

The activity of purified interleukin 2 (IL2), obtained by the recombinant DNA technology, on the proliferative response of human B cells stimulated with low concentrations of anti-mu antibody was investigated. Recombinant IL2 was capable of augmenting the proliferative response of anti-mu-activated B cells and the T cell activation (Tac) antigen was expressed on a substantial proportion of normal B cells stimulated with anti-mu antibody. However, crude supernatants from protein A-stimulated peripheral blood mononuclear cells, which were found to possess both IL2 and B cell growth factor (BCGF) activities, maintained the ability to promote proliferation of anti-mu-activated B cells after depletion of IL2. In addition, supernatants from some T cell clones, apparently free of IL2 activity, displayed strong BCGF activity in the co-stimulation assay with anti-mu antibody. This BCGF activity was found in 25 kDa fractions by gel filtration and it was unaffected by addition to the cultures of anti-Tac antibody, which consistently inhibited the B cell proliferative response promoted by recombinant IL2. The proliferative response of anti-mu-activated B cells to clonal, IL2-free supernatants containing BCGF and recombinant IL2 present together from the beginning of culture was close to the sum of responses to the two stimulants, separately. In addition, the presence of clonal supernatant containing BCGF from the beginning of culture had a synergistic effect in the response of activated B cells to the subsequent addition of IL2, whereas the initial presence of IL2 had no such an effect on the reactivity of anti-mu-stimulated B cells to the late addition of clonal supernatant containing BCGF. The synergistic effect of BCGF in the IL2-promoted B cell proliferation was probably the result of the recruitment of a greater number of IL2-reactive B cells. In fact, the number of Tac-positive cells was significantly higher in 36-h cultures established in the presence of anti-mu antibody plus clonal supernatant containing BCGF than in cultures stimulated with anti-mu antibody alone. Taken together, these data indicate that anti-mu antibody promotes the expression by normal human B cells of distinct receptors for IL2 and a BCGF distinct from IL2. They also suggest that BCGF can exert a synergistic effect in the IL2-promoted proliferation of activated B cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936718     DOI: 10.1002/eji.1830151203

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Analysis of the B-cell growth-promoting activity of human IL-4, the co-stimulatory assay with anti-immunoglobulin antibodies. Comparison with the B-cell growth-promoting activity of other lymphokines.

Authors:  F Almerigogna; M G Giudizi; R Biagiotti; A Alessi; T Defrance; J Banchereau; M Ricci; S Romagnani
Journal:  Immunology       Date:  1989-06       Impact factor: 7.397

2.  Immunomodulatory effects of maternal atrazine exposure on male Balb/c mice.

Authors:  Alexander M Rowe; Kathleen M Brundage; Rosana Schafer; John B Barnett
Journal:  Toxicol Appl Pharmacol       Date:  2006-01-27       Impact factor: 4.219

3.  Direct induction of human B-cell differentiation by recombinant interleukin-2.

Authors:  S Romagnani; G Del Prete; M G Giudizi; R Biagiotti; F Almerigogna; A Tiri; A Alessi; M Mazzetti; M Ricci
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

4.  The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors.

Authors:  T Commes; B Klein; M Jourdan; G Clofent; F Houssiau; J Grenier; R Bataille
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

5.  Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2.

Authors:  T Defrance; B Vanbervliet; J P Aubry; J Banchereau
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.